Fig. 1

Metabolic profiles according to ¹⁸F-FDG-PET/CT correlate with the immune landscape of STS. (A) Distribution of the available frozen samples depending on principal components (PCs) and subsequent metabolic groups. (B) Volcano plot for differential gene expression for the 7 extreme metabolic-low versus 7 extreme metabolic-high comparison. (C) Volcano plot for pathway analysis for the 7 extreme metabolic-low versus 7 extreme metabolic-high comparison. (D) Summary of the main pathways enriched in metabolic-high group. The matrix on the right highlights the main function of those pathways. Associations between the metabolic groups and the CINSARC signature (E) and the TLS status (F). Examples of patients with metabolic-high and –low sarcomas: (G) a 69 years old woman with a 207 mm-long deep-seated high-grade synovial sarcoma of the arm, which was categorized as metabolic-low according to ¹⁸F-FDG-PET/CT (SUV_max=5.1, white arrows) CD8 immunofluorescence showed almost no staining (CD8 + cell density = 1 mm²). (H) The opposite example corresponds to a 77 years old woman with a 94 mm-long deep-seated high-grade undifferentiated pleomorphic sarcoma of the thigh, which was categorized as metabolic-high according to ¹⁸F-FDG PET/CT (SUV_max=22.4, black arrows). CD8 immunofluorescence showed marked and diffuse staining (CD8 + cell density = 539 mm^− 2). Both sarcomas were CINSARC high risk. Other abbreviations: CINSARC: complexity index in sarcoma; FC: fold change